Technical Analysis for ALRN - Aileron Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 1.07 -13.71% -0.17
ALRN closed down 13.71 percent on Monday, May 20, 2019, on 1.25 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ALRN trend table...

Date Alert Name Type % Chg
Expansion Breakdown Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish -13.71%
Lower Bollinger Band Walk Weakness -13.71%
Wide Bands Range Expansion -13.71%

Older signals for ALRN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
Biopharmaceutical Cancer Biology Solid Tumors Cancers Inflammation Molecular Biology Tumor Cell Biology Metabolic Diseases Proteins Oncogenes Lymphomas Treatment Of A Range Of Cancers
Is ALRN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 6.18
52 Week Low 0.52
Average Volume 193,050
200-Day Moving Average 1.9641
50-Day Moving Average 1.7195
20-Day Moving Average 1.5441
10-Day Moving Average 1.3727
Average True Range 0.1399
ADX 27.55
+DI 9.1614
-DI 32.5138
Chandelier Exit (Long, 3 ATRs ) 1.3803
Chandelier Exit (Short, 3 ATRs ) 1.4597
Upper Bollinger Band 1.9454
Lower Bollinger Band 1.1428
Percent B (%b) -0.09
BandWidth 51.978499
MACD Line -0.1391
MACD Signal Line -0.0924
MACD Histogram -0.0467
Fundamentals Value
Market Cap 15.75 Million
Num Shares 14.7 Million
EPS -41.73
Price-to-Earnings (P/E) Ratio -0.03
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.35
Resistance 3 (R3) 1.37 1.30 1.30
Resistance 2 (R2) 1.30 1.23 1.29 1.29
Resistance 1 (R1) 1.18 1.18 1.15 1.16 1.27
Pivot Point 1.11 1.11 1.09 1.10 1.11
Support 1 (S1) 1.00 1.04 0.96 0.98 0.87
Support 2 (S2) 0.93 1.00 0.92 0.85
Support 3 (S3) 0.81 0.93 0.84
Support 4 (S4) 0.79